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Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor
patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after
stem cell transplantation (SCT) has been reported to be correlated with a higher overall
survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also
addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM
cells at specific time points: at diagnosis and before and after autologous stem cell
transplantation. Remarkably, after cytokine stimulation, the patients’ NK cells did not
significantly differ from those of healthy donors. In a small cohort of MM patients, we
were able to isolate autologous tumor cells, and we could demonstrate that IL-2/15
stimulated autologous NK cells were able to significantly improve their killing capacity
of autologous tumor cells. With the aim to further improve the NK cell killing capacity
against MM cells, we investigated the potential use of NK specific check point inhibitors
with focus on NKG2A because this inhibitory NK cell receptor was upregulated following
ex vivo cytokine stimulation and MM cells showed HLA-E expression that could even be
increased by exposure to IFN-γ. Importantly, blocking of NKG2A resulted in a significant
increase in the NK cell-mediated lysis of different MM target cells. Finally, these results let
suggest that combining cytokine induced NK cell activation and the specific check point
inhibition of the NKG2A-mediated pathways can be an effective strategy to optimize NK
cell therapeutic approaches for treatment of multiple myeloma.
Keywords: multiple myeloma, autologous stem cell transplantation, NK cells, adoptive cell therapy, NKG2A
blocking, checkpoint inhibition
INTRODUCTION
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells (PCs). The
hallmarks of the disease are an excess of monoclonal PCs in combination with monoclonal
protein in the blood and/or urine (1). Standard therapy typically involves autologous stem cell
transplantation (autoSCT) after induction, followed by high-dose chemotherapy treatment (2).
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Importantly, given the risk of the treatment and its side effect,
autoSCT is usually recommended only for youngest patients,
accounting for approximately 30–40% of the patients with MM.
However, the majority of patients will relapse within 2–3 years
from the initiation of treatment, and the overall survival (OS)
is still limited (3). Nevertheless, significant advances have been
made in the treatment of MM by a combination of standard
chemotherapy plus novel immunomodulatory drugs (IMiDs) or
proteasome inhibitors, such as lenalidomide or bortezomib (4).
Another promising approach is the immunotherapeutic
treatment with natural killer (NK) cells, as they present the
benefit of enhanced graft-versus-tumor (GvT) effect with a low
risk of graft-versus-host disease (GVHD) [for review, see (5–
7)]. Furthermore, in MM patients, an elevated number of NK
cells directly correlates with a lower tumor burden (8). NK
cells, which were first described by Kiessling et al., are part
of the innate immune system. NK cells are highly attractive
because they are not antigen specific, like T and B cells. Their
activity is regulated based on the diverse expression of activating
and inhibiting receptors on their surface, by which they also
achieve self-tolerance (9–11). After recognition of an infected
or malignant cell, NK cells can kill their target by releasing
cytoplasmic perforin or granzyme, leading to death receptor-
mediated apoptosis or cytokine release (12). Human NK cells
are characterized by the expression of CD56 and CD16 and are
divided into two distinct subtypes. The more immature subset
is characterized by high expression of CD56 and low or no
expression of CD16; this subset is mainly situated in the lymph
nodes and secondary lymphoid tissues. After maturation, the NK
cell population comprises CD56dim CD16bright cells and is mainly
found in the bone marrow, blood and spleen (13, 14). This subset
has high cytotoxic capabilities and represents approximately 90%
of all NK cells in the peripheral blood (15). Furthermore, NK
cells have a regulatory effect on other immune cells by secreting
soluble factors, such as tumor necrosis factor alpha (TNF-α),
interferon gamma (IFN-γ), granulocyte macrophage colony-
stimulating factor (GM-CSF) and macrophage inflammatory
proteins (MIPs) (16, 17).
For the application in immunotherapy, NK cells can be
isolated from either patient or healthy donor derived PBMCs
or differentiated from pluripotent stem cells. For most clinical
applications, the NK cells are expanded by ex vivo culture. To
further increase the effect of the therapy, it is important to
achieve the optimal NK cell antitumor activity by using the
right stimulation protocols. To date, the most common protocols
stimulate NK cells with cytokines such as IL-2, IL-15 and IL-21
that induce high cytotoxicity or with IL-12, 15 and 18 to favor NK
cell memory (18). Apart from stimulation with interleukins, NK
cells can also be co-cultured with so-called accessory or feeder
cells such as irradiated, allogeneic PBMCs or different cell lines
Abbreviations: MM, multiple myeloma; CD, cluster of differentiation; CT,
chemotherapy; DAMPs, damage associated molecular patterns; DCs, dendritic
cells; DNA, deoxyribonucleic acid; GM-CSF, granulocyte macrophage colony-
stimulating factor; HD, healthy donors; NK cells, natural killer cells; IFN,
Interferon; Il, Interleukin; ns, not significant; Pt, patients; PB, peripheral blood;
BM, bone marrow; TP0, treatment point 0; TP1, treatment point 1; TP2, treatment
point 2; FACS, fluorescence activated cell sorting; IL15RA, IL-15 receptor alpha.
such as K562 to further enhance NK cell expansion [for review
see (18)].
A novel approach toward NK cell therapy is not only to
activate them ex vivo but also to release the immune system from
inhibition by specifically targeting immunologic checkpoints.
Inhibitory receptors expressed on the NK cell surface are
members of the KIR family and NKG2A. KIR receptors interact
with MHC I molecules, and studies have shown that a transfer of
KIR-ligand mismatched NK cells led to a lower relapse rate and
a greater GvT effect due to their enhanced alloreactivity (19, 20).
Moreover, several antibodies that specifically target KIR receptors
have been tested or are currently in clinical trials to evaluate their
efficacy against different malignancies (21).
However, due to different KIR receptor expression profiles
in patients, a therapeutic targeting of selected KIR receptors
could lead to a better response in some patients and a worse
response in others. Moreover, the results of a clinical phase II
trial testing a KIR2D specific antibody showed that treatment
with the antibody led to a significant decrease in NK cell activity,
directly correlating with loss of KIR2D surface expression (22).
In this aspect, NKG2A could be a better therapeutic target, as
it is broadly expressed on NK cells and binds specifically to
HLA-E that is expressed on most malignant target cells (23).
Additionally, overexpression of HLA-E in different tumors has
been reported to correlate with shorter disease-free or overall
survival (24, 25). In MM, HLA-E is highly expressed by primary
cells, and it abolishes the overall response of NKG2A+ NK
cells (26). Furthermore, Sarkar and colleagues postulated that
the most potent NK cell subset for clinical application would
be NKG2A-negative and KIR-ligand mismatched. Interestingly,
NKG2A is the first inhibitory receptor that is reconstituted after
SCT (27, 28). This observation might also highlight the possible
relevance of NKG2A as a therapeutic target in the context of
allogeneic SCT.
Overall, these findings led us to further investigate the effects
of cytokine-induced NK cell activation in combination with the
specific checkpoint inhibition of the NKG2A-mediated pathway
as a potential strategy to optimize NK cell therapeutic approaches
against MM.
RESULTS
Cytokine Stimulation Significantly
Increases the NK Killing Ability of Both
Patient and Healthy Donor NK Cells
Against MM Cell Lines
First, we aimed to test the “natural” ability of NK cells to
kill different MM cell lines. Therefore, we isolated peripheral
blood (PB) NK cells from healthy donors (HD) or untreated
MM patients (Pt) at first diagnosis and co-cultured them with
three different MM cell lines (U266, OPM-2, and LP-1) for 24 h
(Figure 1A). The specific lysis of patient NK cells in resting
conditions was approximately 10% against all three cell lines,
with a trend toward reduced cytotoxic capacity compared to
HD NK cells. To improve NK cell killing capacity against MM
cells, we then stimulated both patient and donor NK cells for
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FIGURE 1 | Cytokine stimulation significantly increases the NK killing ability of both patient and healthy donor NK cells against MM cell lines. (A) Resting and (B)
activated (IL-2 + IL-15) NK cells isolated from patients or healthy donors were co-cultured for 24 h with the CFSE-stained multiple myeloma cell lines, LP-1, OPM-2
and U266. The percentage of dead tumor cells was determined with a live-dead stain (DAPI) via flow cytometry after 24 h of co-culture. To further demonstrate the
differences in the specific lysis of tumor cells between resting and activated tumor cells, the values for NK cells isolated from (C) healthy donors and (D) patients were
compared. Data on resting NK cells are depicted in blue, whereas data on activated NK cells are shown in red. Data from patient samples are shown with filled-in
bars, whereas data from healthy donor samples are shown with empty bars. NK cells and tumor cells were co-cultured with a 2:1 E-T ratio. For healthy donor data,
5–6 individual experiments were performed. For patient samples, 9 individual experiments with resting NK cells and 13 individual experiments with 7 days cytokine
activated NK cells were performed. Statistical analysis with two-way ANOVA + Sidak’s multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
7 days with IL-2/15 cytokine cocktail (IL-2: 100 U/ml; IL-15:
10 ng/ml) prior to performing the killing assay (Figure 1B). Of
note, both patient and donor cytokine-activated NK cells showed
a significantly enhanced killing capacity against the different MM
cell lines compared to that of the resting NK cells (Figures 1C,D).
Cytokine Stimulation Significantly
Increases the Expression of Numerous NK
Cell Activation Markers
Given the strong and positive impact of cytokine stimulation
on NK cells, we asked whether the expression of NK cell
receptors and surface molecules might be modified. Therefore,
we analyzed the expression levels of 19 markers by flow
cytometry, including activating and inhibitory receptors, markers
of activation and maturation, death receptors, homing receptors
and exhaustion markers. First, we compared their expression in
resting conditions in patients and healthy donors (Figure 2A).
The only significant difference was the higher expression
of TRAIL on patient NK cells. Next, we addressed the
expression following in vitro cytokine stimulation for 7 days
(Figure 2B). Interestingly, patient NK cells show a higher
expression of activating NKp30, as well as, CD57 and TRAIL
receptor. In Figure 2C the expression pattern of the 19 surface
molecules before and after cytokine activation in healthy
donor NK cells is depicted. Interestingly, many activating
receptors and markers are strongly and significantly increased
after cytokine stimulation, e.g., NKp30, NKp44, CD69, CD25,
CD57, and TRAIL. This finding can explain the positive
impact on the NK cell mediated killing ability of MM
cells. Of note, the inhibitory receptor NKG2A is also highly
upregulated after cytokine stimulation. Similar modifications
have been observed for NK cells isolated from patients
(Figure 2D).
BM-Derived NK Cells Show a Similar
Phenotype and Killing Behavior to Those of
PB-Derived NK Cells in MM Patients
As MM cells reside in the BM, we further asked whether
and how patient NK cells derived from the bone marrow
would differ from PB NK cells in newly diagnosed and still
untreated MM patients (TP0). For that purpose, we performed
cytotoxicity assays in resting and activating conditions with
NK cell isolated from either BM or PB, as shown in Figure 3.
These analyses show no significant differences in the killing
activity of patient BM and PB NK cells. There is, however, a
less significant increase in killing after the activation of BM
NK cells, compared with PB NK cells (Figure 3C). Similarly,
we also investigated the phenotype of BM NK cells. While
BM NK cell receptor expression was similar to that of PB NK
cells under resting conditions (Figure 4A), following cytokine
stimulation, the BM NK cells showed significantly lower levels of
NKp30 (Figure 4B). A comparison of the BM NK cell phenotype
before and after activation showed, also in this compartment, a
significant increase in the activating markers NKp44, CD69, and
CD25 (Figure 4C).
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FIGURE 2 | Cytokine stimulation significantly increases the expression of many NK cell activation markers. Isolated NK cells from patients and healthy donors were
stained with fluorochrome-conjugated antibodies to determine surface marker expression (A) before and (B) after activation with IL-2 and Il-15. NK cell phenotypes
before and after stimulation were also compared for NK cells isolated from (C) healthy donors and (D) patients. For healthy donor samples, 17 individual experiments
with resting NK cells and 14 individual experiments with activated NK cells were performed (n = 14–17). For patient samples, 14 individual experiments with resting
NK cells and 15 individual experiments with 7 days cytokine activated NK cells were performed (n = 14–15) Statistical analysis with two-way ANOVA + Sidak’s
multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Cytokine Stimulation Significantly
Increases the NK Cell Killing Ability of
Patient NK Cells at Various Treatment
Points
Next, we investigated whether there were differences in the killing
ability of MM cells and in the cytokine susceptibility of patient
NK cells at different time points (TPs) during the treatment
course. Therefore, PB samples from several newly diagnosed
MM patients at different treatment stages were collected, at
diagnosis (TP0), after induction therapy but before high-dose
chemotherapy and autoSCT (TP1) and after hematological
reconstitution after autoSCT (TP2) (Figure 5A). Patient numbers
and characteristics are summarized in Table 1.
Cytokine-activation of NK cells significantly improved patient
NK cell killing activity, especially toward the cell line U266 and
LP1 (Figure 5B). There were however no significant differences
in the lysis at different TPs.
Moreover, we monitored the expression pattern of 19 surface
molecules of interest during the course of therapy and before and
after cytokine stimulation, as shown in Figure 6. The induction
therapy seemed to have a slightly negative impact on the NK
cell activation status in resting conditions; the activation marker
NKp30 and the BM homing receptor CXCR4 are significantly
downregulated at TP1 (Figure 6A). The decrease of the activating
receptors NKp30 and TRAIL and the increase of NKG2A could
partially explain the reduced effect of the cytokine activation on
the specific lysis levels (Figure 5B). Interestingly, at the end of the
therapy (TP2) andmore markedly after activation, the expression
levels of several markers were restored, as in the case of DNAM1,
NKp30, TRAIL, and CXCR4 (Figure 6A). However, NK cells at
TP2 seem to have an overall more immature phenotype due to
the downregulation of CD57, CD16, and KIR2D expression and
the upregulation of NKG2A expression (Figure 6). These data
confirmed the downregulation of CD57, CD16, and KIR2D after
therapy and in particular at TP2, as well as, the upregulation of
NKG2A, indicating a more immature NK cell phenotype and
possibly lower ADCC capacity of NK cells at TP2 (Figure 6B).
Cytokine Stimulation Significantly
Increases the Killing Ability of MM Patient
NK Cells Even Against Autologous MM
Cells
To further explore the cytotoxic potential of NK cells, we decided
to study patients’ killing ability against autologous tumor cells.
With that aim, we isolated autologous primary tumor cells from
some patients’ BM aspirates that were subsequently used as a
target for PB and BMNK cells from the sameMMpatients before
and after cytokine stimulation (Figure 7A). Remarkably, both
PB and BM patient NK cells in resting conditions were unable
to kill autologous MM tumor cells. However, after cytokine
stimulation, patient NK cells strongly and significantly increased
their cytotoxic activity even against autologous MM tumor cells
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FIGURE 3 | NK cells isolated from peripheral blood or bone marrow exhibit a similar cytotoxic potential and phenotype. (A) Resting and (B) activated NK cells isolated
from peripheral blood and bone marrow of patients were co-cultured for 24 h with the CFSE-stained multiple myeloma cell lines LP-1, OPM-2 and U266 to compare
the specific lysis of target cells. (C) Comparison of BM NK cytotoxic potential before and after activation. The percentage of dead tumor cells was determined with a
live-dead stain (DAPI) via flow cytometry after 24 h of co-culture. For bone marrow samples, 9 individual experiments with resting NK cells and 7 individual experiments
with 7 days cytokine activated NK cells were performed (n = 7–9). For peripheral blood samples 10 individual experiments were performed (n = 10). Statistical
analysis with two-way ANOVA + Tukey’s multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(Figure 7B). Of note, there were no significant differences in the
killing capacity of PB and BM NK cells.
Expression Levels of NK Cell Receptor
Ligands Do Not Correlate With Differences
in the Susceptibility of NK Cell Killing
We performed a detailed flow cytometry phenotyping of the
various MM target cell lines and MM primary cells to define
their expression levels of 12 surface markers, with a special focus
on the ligands for NK cell receptors (Figures 7C, 8). The three
MM cell lines (Figure 8A) revealed differences in the expression
levels of several surface markers such as FAS-R, CD56, and
CD48. However, the three cell lines only slightly differed in
the levels of ligands for the activating and inhibitory receptors.
Notably, the phenotype did not correlate with the different
levels of susceptibility to NK cell killing. Moreover, we treated
the MM cell lines with IFN-γ (Figure 8B) to investigate their
phenotype under pro-inflammatory conditions, and we observed
one major change, namely, the strong increase in HLA-E
expression.
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FIGURE 4 | NK cells isolated from peripheral blood or bone marrow exhibit a similar cytotoxic potential and phenotype. The phenotypes of (A) resting and (B)
activated NK cells isolated from peripheral blood and bone marrow of patients at TP0 were compared by staining with fluorochrome-conjugated antibodies.
(C) Comparison of the BM NK phenotype before and after activation. For bone marrow samples, 7 individual experiments with resting NK cells and 4 individual
experiments with 7 days cytokine activated NK cells were performed (n = 4–7). For peripheral blood samples, 14 individual experiments with resting NK cells and 15
individual experiments with activated NK cells were performed (n = 14–15). Statistical analysis with two-way ANOVA + Sidak’s multiple comparison: *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
The Combination of NKG2A Blocking With
Cytokine Stimulation Further Improves NK
Cell Killing Activity Against MM Cells
Given that the inhibitory receptor NKG2A was the only
inhibitory receptor upregulated following cytokine stimulation,
we hypothesized that blocking this inhibitory NK cell checkpoint
could further improve the lysis of MM target cells by NK cells
(Figure 9). Therefore, NK cells from patients were incubated
with a blocking antibody or the control isotype prior to the
cytotoxicity assay (Figure 9A). Importantly, blocking NKG2A
resulted in a clear increase in the NK cell-mediated killing of
OPM-2 and LP-1 cell lines. Hoping to achieve the possible use
of third party or donor NK cells for adoptive therapy in MM,
we examined whether the same effect could be seen using HD
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FIGURE 5 | Cytokine stimulation significantly increases the NK killing ability of patient NK cells at various treatment points. (A) NK cells from patients were isolated at
different treatment points: TP0 after diagnosis, TP1 during high-dose chemotherapy and TP2 more than 21 days after stem cell transplantation. (B) The isolated NK
cells were co-cultured with the CFSE-stained multiple myeloma cell lines LP-1, OPM-2 and U266 either directly after isolation or after seven days of pre-activation with
IL-2 and IL-15. The percentage of dead tumor cells was determined with a live-dead stain (DAPI) via flow cytometry after 24 h of co-culture. NK cells and tumor cells
were co-cultured with a 2:1 E-T ratio. For TP0, 7 individual experiments with resting NK cells and 15 individual experiments with 7 days activated NK cells were
performed (n = 7–15). For TP1, 7 individual experiments with resting NK cells and 5 individual experiments with activated NK cells were performed (n = 5–7). For TP2,
3 individual experiments with resting NK cells and 4 individual experiments with activated NK cells were performed (n = 3–4). Statistical analysis with two-way ANOVA
+ Tukey’s multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
NK cells. HD NK cell show a significant better lysis against the
targets U266 and LP-1. Importantly, the improvement of NK cell
mediated killing capacity was even stronger when the MM cell
lines were previously treated with IFN-γ and were highly HLA-E
positive (Figure 9B).
DISCUSSION
MM is a highly aggressive plasma cell neoplastic disorder, and
despite recent therapeutic advancements, it is still considered
an incurable disease. Immunotherapy, including the use of
cytokines, checkpoint inhibitors or cellular immunotherapeutics,
holds great new promises to expand anti-myeloma treatment
options. Because of its given antitumor activity, adoptive NK cell-
based immunotherapy represents a potential treatment approach
for myeloma patients.
In our study, we demonstrated that NK cells activated with IL-
2 and IL-15 were able to efficiently kill multiplemyeloma cell lines
and autologous myeloma cells. Importantly, their killing activity
was independent of the NK cell source from PB or BM or the time
point of their isolation during myeloma treatment. Remarkably,
their anti-myeloma activity could be further enhanced by an
NKG2A checkpoint blockade.
Initially, it has been reported that NK cells from myeloma
patients have a defect in their cytotoxic activity (29–31) and
that myeloma cells are becoming more resistant to NK cell
killing during disease progression (32). As an example of tumor
immune evasion strategies it has been reported that high TGF-
β levels in the tumor environment decrease the ability of NK
cells to respond to IL-12 and IL-15 (33). On the other side,
expression of IL-15 receptor and autocrine production of IL-15
has been suggested as mechanism of tumor propagation in MM
(34). Moreover, the expression of activating NK cell receptors
(e.g., NCR, NKG2D, 2B4, DNAM1) is known to be decreased
in MM patients (35, 36). Although our data only demonstrated
a difference in membrane bound TRAIL expression on resting
NK cells of healthy donors and MM patients, the NK cell
mediated cytotoxic activity against myeloma cell lines was only
marginal.
However, upon ex vivo cytokine stimulation, the cytotoxicity
of NK cells against multiple myeloma cell lines significantly
improved. Furthermore, autologous inhibition was overcome
and led to increased anti-myeloma activity even against
autologous, primary myeloma cells. This result is in line with
other studies investigating ex vivo NK cell expansion/activation
protocols for anti-myeloma immunotherapy.
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TABLE 1 | Patients characteristics.
Pt. Nr MM type %PC–
BM
ISS
stage
Risk Response
t1
Response
t2
#1 lgA kappa 30 I SR PR VGPR
#2 kappa 20 III n.a. n.a. n.a.
#3 lgG kappa 80 III SR MR VGPR
#4 lgA lambda 25 III HR VGPR PR
#5 lgG kappa 40 I SR n.a. n.a.
#6 lgA kappa 20 I SR PR VGPR
#7 lgG kappa 20 I SR VGPR CR
#8 lgG kappa 90 II SR PR VGPR
#9 lgG kappa 25 I SR VGPR VGPR
#10 lgG kappa 20 II SR VGPR CR
#11 lgG lambda 15 I SR VGPR CR
#12 lgG lambda 50 I SR VGPR CR
#13 lgG kappa 30 I HR VGPR n.a.
#14 lgG kappa n.a. III n.a. n.a. n.a.
#15 lgG kappa 40 III n.a. n.a. n.a.
#16 kappa n.a. I n.a. n.a. n.a.
Sixteen patients with newly diagnosed multiple myeloma have been included in this study.
Fifteen patients had symptomatic myeloma and needed an immediate treatment. Of
these 15 patients, 11 patients were treated with a bortezomib-based triplet, followed
by stem cell mobilization and high-dose chemotherapy with 200 mg/m2 melphalan. The
remaining 4 patients were treated with conventional dose bortezomib/ dexamethasone
or lenalidomide/ dexamethasone. Responses (according to IMWG) were evaluated after
induction treatment (t1), and after minimum 60 days at hematological reconstitution after
high-dose chemotherapy (t2). Risk stratification delineates the following cytogenetic risk
factors by FISH: high risk (HR) with presence of t(4;14), or t(14;16), or del(17p); standard
risk (SR) with Absence of above named. PC, plasma cell; BM, bone marrow; MR,
minimal response; CR, complete remission; PR, partial remission; VGPR, very good partial
remission; n.a., not available.
One study established a GMP-compliant protocol to expand
NK cells from MM patients using IL-2 and anti-CD3 for 20
days, leading to a sufficient NK cell expansion of an average 511-
fold (37). Importantly, only activated and expanded NK cells
were able to kill autologous myeloma cells in vitro, without any
cytotoxicity against autologous CD34+ cells. This effect was time
dependent since the NK cells’ anti-myeloma activity was only
marginal after a 5-day stimulation period.
Another approach was to use a genetically modified K562
cell line expressing the 41BB-ligand and IL-15. NK cells from
healthy donors andmyeloma patients were successfully expanded
and able to kill allogeneic and autologous primary myeloma
cells in vitro and in an in vivo mouse model (38). Again, only
expanded NK cells demonstrated a significant killing activity
against myeloma cells, whereas non-expanded NK cells did not.
In accordance with our data, expanded NK cells from HD and
MM patients demonstrated similar cytotoxic activities against
allogeneic myeloma targets, indicating that ex vivo cytokine
stimulation is able to overcome the NK cell cytotoxicity defects
of myeloma patients.
The mechanism behind their improved cytotoxicity has been
attributed to the increased expression of activating NK cell
receptors (e.g., NKG2D, DNAM1, and NCRs) and cytotoxic
effector molecules (e.g., granzyme B and perforin), as well as,
membrane bound death receptor ligands (e.g., TRAIL). Their
contributions have been demonstrated by performing blocking
experiments upon NK cell cytokine stimulation (32, 38, 39),
which is of particular importance since anti-myeloma drugs
are known to increase activating or decrease inhibitory NK
cell receptor ligands on myeloma cells (40–42). We observed
an increase in the surface expression of activating receptors
upon cytokine stimulation. In addition, TRAIL expression
was significantly increased upon cytokine stimulation on
myeloma patients’ NK cells, which is in concordance with the
results of previous reports demonstrating TRAIL upregulation
and improved NK cell cytotoxicity upon IL-2 and/or IL-15
stimulation (43, 44). Based on this knowledge, the first clinical
trials using adoptive NK cell transfer to treat myeloma patients
have been completed. While one trial used the allogeneic NK cell
line, NK-92, within a phase-I dose-escalating trial for treating
refractory hematological malignancies in a non-transplantation
setting (45), two other trials were performed within an autoSCT
setting. The first used haploidentical, KIR-ligandmismatchedNK
cells expanded with IL-2 and anti-CD3, demonstrating the safe
engraftment of autologous stem cells with no signs of GVHD
in treated myeloma patients (46). Similar safety results were
obtained in a second trial expanding NK cells using irradiated
K562 cells expressing membrane bound IL-21 in combination
with IL-2 (47).
Based on these first in-human trials, we investigated the best
time point for harvesting NK cells to expand them for adoptive
NK cell transfer within an autoSCT setting. Interestingly, in this
study independent of prior treatments with the proteasome-
inhibitor bortezomib, immune modulating substances (IMiDs)
such as lenalidomide or chemotherapeutics including melphalan,
NK cells isolated at all chosen TPs demonstrated similar cytotoxic
activity against myeloma cell lines. This result was surprising
as an NK cell activating effect of IMiDs and a more inhibitory
effect of proteasome inhibitors have been previously reported
(for review see (48)). Furthermore, despite the differential
expression of activating and inhibitory receptors in resting NK
cells, especially the upregulation of NKG2A expression and the
downregulation of CD57 expression at TP2, indicate a more
immature NK cell phenotype, in line with earlier reports (28). In
addition, lower TRAIL expression upon cytokine expression on
NK cell from TP1 did not seem to have a negative influence on
their anti-myeloma activity.
Therefore, we propose that NK cells can be freshly isolated
before the start of high-dose chemotherapy (HD) and autoSCT
in order to be activated, expanded and re-infused before or
after autoSCT. Using freshly isolated NK cells is of importance
since adoptive NK cell transfer studies have demonstrated that
the use of fresh NK cells may be more beneficial than using
cryopreserved cells (49, 50).
Although we observed increased anti-myeloma activity and
expression of activating NK cell receptors, there was a significant
upregulation of the inhibitory receptor NKG2A, while other
receptors such as KIR2D or PD1 were not upregulated. This
result is in contrast to other reports, which have demonstrated
the strong upregulation of PD1 upon cytokine stimulation
(51). In addition, CD57 expression was downregulated on our
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FIGURE 6 | Expression of several NK cell markers significantly changed between different treatment points. NK cells from patients were isolated at different treatment
points: TP0 after diagnosis, TP1 during high-dose chemotherapy and TP2 more than 21 days after stem cell transplantation. After isolation, NK cells were stained with
fluorochrome-conjugated antibodies to determine surface marker expression (A) before and (B) after activation with IL-2 and Il-15. For TP0, 11 individual experiments
with resting NK cells and 15 individual experiments with activated NK cells were performed (n = 11–15). For TP1, 10 individual experiments with resting NK cells and
16 individual experiments with 7 days activated NK cells were performed (n = 10–16). For TP2, 5 individual experiments with resting NK cells and 7 individual
experiments with activated NK cells were performed (n = 5–7). Statistical analysis with two-way ANOVA + Sidak’s multiple comparison: *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
activated NK cells, corresponding to amore immature phenotype
(52) as has been described by others. In addition, also CD16
was downregulated which might reduce the NK cell ADCC
capacity. Despite their more immature phenotype, those NK
cells were multifunctional since they demonstrated increased
cytokine production, proliferation capacity and degranulation
upon target cell recognition. In addition, cytotoxic molecules
were strongly upregulated (51). These data indicate that the
classical view of NKG2A+ NK cells as being more immature and
the main cytokine producers does not hold true when the cells
are stimulated with cytokines.
NKG2A is known to interact with HLA-E and is known
to be increased on myeloma cell lines. Although HLA-E was
low on our myeloma cell lines, its expression was increased
on primary myeloma cells. This finding is in line with other
reports demonstrating higher levels of HLA-E on primary
myeloma cells than on cell lines, which can be upregulated
upon in vivo transfer (26). In addition, HLA-E expression
was upregulated upon IFN-γ treatment, diminishing their
susceptibility toward NK cell treatment, which was reverted
upon blocking the NKG2A-/HLA-E interaction. The importance
of the NKG2A/HLA-E interaction has been demonstrated for
other diseases, e.g., within a humanized, post-transplantation
model, which demonstrated that re-constituted NKG2A+ NK
cells were able to kill human primary leukemia cells when
mice were injected with an anti-human NKG2A antibody (53).
In addition, blocking the NKG2A/HLA-E interaction was able
to restore NK cell dysfunction against CLL cells (54). This
finding has led to different clinical phase 1 trials to evaluate
the efficacy and safety of the NKG2A blockade in patients with
CLL disease (NCT02557516) or in a post-allogeneic SCT setting
(NCT02921685).
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FIGURE 7 | Pre-activation of NK cells significantly increases autologous tumor cell lysis. (A) Schematic of the experimental procedure. On d0, NK cells from peripheral
blood were isolated and used for cytotoxicity assays at d0, before activation, and d7, after activation. On d7, MM cells and NK cells were isolated from BM aspirates.
Those cells were also used for cytotoxicity assays at d7, before activation, and d14, after activation. (B) Resting and 7 days cytokine activated NK cells isolated from
peripheral blood and bone marrow of patients were co-cultured for 24 h with CFSE-stained autologous multiple myeloma cells to compare the specific lysis of target
cells. The percentage of dead tumor cells was determined with a live-dead stain (DAPI) via flow cytometry after 24 h of co-culture. NK cells and tumor cells were
co-cultured with a 2:1 E-T ratio. (C) From patients, isolated primary multiple myeloma cells were stained with fluorochrome-conjugated antibodies to determine
marker expression. For the bone marrow samples, 9 individual experiments with resting NK cells and 5 individual experiments with activated NK cells were performed
(n = 5–9). For the peripheral blood samples, 9 individual experiments were performed (n = 9). For the phenotyping of autologous MM cells, 5 individual experiments
were performed. Statistical analysis with two-way ANOVA + Tukey’s multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
In summary, our data provide evidence for the use of ex
vivo cytokine-activated NK cells as an immunotherapy to treat
myeloma patients within an autoSCT setting in combination with
NKG2A blockade.
MATERIALS AND METHODS
NK Cell Isolation and Culture
Blood samples were obtained from healthy donors or from
diagnosed MM patients in accordance with the Declaration of
Helsinki. All subjects provided written, informed consent. This
study was carried out in accordance with the recommendations
of the Ethics Committee of the University Hospital Frankfurt.
The protocol of this study (SHN-02-2015) was approved by the
abovementioned committee. Patient numbers and characteristics
are summarized in Table 1. Patient selection was randomly at the
onset of MM diagnosis prior to any treatment. The age range for
patients was from 45 to 70 years, but only from 29 to 64 years for
healthy donors.
Blood from patients was collected at three different treatment
points (TP0 after diagnosis, TP1 in the pause before high-dose
chemotherapy and autoSCT, TP2 >21 d after SCT). Peripheral
and bone marrow blood mononuclear cells were isolated by
Ficoll density gradient centrifugation (Biochrom, #L6115). NK
cells were enriched by negative selection of NK cells with
an EasySep NK Cell Enrichment Kit (StemCell Technologies,
#19055) according to the manufacturer’s protocol. NK cell purity
was assessed by flow cytometry and was >90% with the used
isolation method. Cells were cultured in X-VIVO 10 (Lonza,
#BE04-743Q) medium supplemented with 5% heat-inactivated
human plasma (DRK Blutspendedienst) and 1% penicillin
with streptomycin (Invitrogen, #15140-122). NK cells were
expanded ex vivo by additionally supplementing the medium
with IL-2 (100 U/ml) (Peprotech, #200-02) and IL-15 (10 ng/ml)
(Peprotech, #200-15). Every third day 80 µl of old medium
were removed and100 µl of fresh medium with cytokines were
added to the wells. All cells were maintained at 37◦C with
5% CO2 atmospheric conditions. Unless otherwise stated, NK
cells were used in the experiments after 7 days of culture with
IL-2/15.
Culture and Treatment of MM Cells
Autologous MM cells were isolated from bone marrow aspirates
using CD138 MicroBeads and a MidiMACS Separator (Miltenyi
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FIGURE 8 | Determination of the expression of surface molecules on multiple myeloma cells. (A) The marker expression of different multiple myeloma cell lines was
measured via FACS analysis by staining the cell lines LP-1 (black), OPM-2 (dark gray) and U266 (light gray) with fluorochrome-conjugated antibodies. (B) To further
increase the expression of HLA-E, the multiple myeloma cell lines were incubated for 24 h with 25 nM IFN-γ before measuring surface marker expression via flow
cytometry. For phenotyping the MM cells, five individual experiments were performed (n = 5). For phenotyping experiments after stimulation with IFN-γ, 3 individual
experiments were performed (n = 3). Statistical analysis with two-way ANOVA + Sidak’s/Tukey’s multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001.
Biotech, #130-042-30, #130-097-614). Cells were cultured in
X-VIVO 10 (Lonza, #BE04-743Q) medium supplemented with
5% heat-inactivated human plasma (DRK Blutspendedienst)
and 1% penicillin with streptomycin. Multiple Myeloma
cell line originally were received from the DSMZ (Leibniz-
Institut DSMZ-German Collection of Micro-organisms
and Cell Cultures GmbH). To further confirm the identity
of the cell lines we performed phenotypic flow cytometry
analysis (Supplemental Figures 4, 6), HLA-ABC genotyping
(Supplemental Table 1) and and short tandem repeat (STR)
analysis of the cell line U266 (Supplemental Table 2). Taken
all the data together, we could confirm the identity of our
MM cell lines by different orthogonal methods, demonstrating
therefore absence of cross-contamination. The MM cell
line LP-1 was cultured in IMDM supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin and
streptomycin and glutamine. The cell lines OPM-2 and U266
were cultured in RPMI 1640 + Glutamax (Life Technologies,
#31870-025) supplemented with 10% heat-inactivated fetal
bovine serum and 1% penicillin with streptomycin. All
cells were maintained at 37◦C with 5% CO2 atmospheric
conditions.
FACS Phenotyping and Purity Check
For the flow cytometric measurements, 1 × 105-106 cells
were used per reaction tube. Cells were stained for 20min
at 4◦C. For NK cell phenotyping experiments, cells were
stained with the following antibodies: 7AAD PerCP (#559925),
CD107a APC-H7 (#561343), CD184 PE-Cy7 (#560669), CD226
FITC (#559788), CD25 BV605 (#562660), CD335 PE (#331908),
CD56 BV421 (#562751), CD69 BV605 (#562989) (all from BD
Biosciences), CD16 APC ALEXA700 (#302025), CD19 PerCP
(#302228), CD215 APC (# 330209), CD253 PE (# 308206),
CD3 PerCP (# 300428), CD336 PE (# 558563), CD57 APC
(# 322314) (all from Biolegend), CD138 BV510 (# 130-101-
169), CD14 PerCP (# 130-094-969), CD244 PE-Cy7 (# 130-
099-074), CD279 PE (# 130-096-164), KIR2D FITC (# 130-098-
689) (all from Miltenyi Biotech), CD159a PE (PNIM3291U),
CD314 APC (# A22329) (both from Beckman Coulter) and
CD159c ALEXA488 (# FAB138G-100), CD337 ALEXA488 (#
Frontiers in Immunology | www.frontiersin.org 11 November 2018 | Volume 9 | Article 2743
Tognarelli et al. Activating NK Versus Multiple Myeloma
FIGURE 9 | Functional blockade of NKG2A significantly increases NK cell cytotoxic potential. Isolated NK cells from (A) patients and (B) healthy donors were
pre-activated by stimulating them with IL-2 and IL-15 for seven days and then co-cultured with different multiple myeloma cell lines, as well as, autologous, primary
cells for 24 h. Prior to co-culture, the NK cells were treated with either an anti-NKG2A or isotype antibody to functionally block NKG2A on the NK cell surface. The
percentage of dead tumor cells was determined with a live-dead stain (DAPI) via flow cytometry after 24 h of co-culture. NK cells and tumor cells were co-cultured with
a 2:1 E-T ratio. For patient samples, 8 individual experiments for resting + isotype, 9 individual experiments for activated + isotype and activated + a-NKG2A were
performed (n = 8–9). For healthy donor samples, 5 individual experiments were performed (n = 5). Statistical analysis with two-way ANOVA + Sidak’s multiple
comparison: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
FAB1849G) (both from R&D). Purity of the isolated NK cells
was checked with the following: DAPI (AppliChem), CD56
FITC (# 345811) (BD Biosciences), CD16 APC ALEXA700 (#
302025), CD19 PerCP, CD3 APC (# 300412) (all from Biolegend),
CD45 PE (# MHCD4504) (Invitrogen) and CD138 BV510
(Miltenyi Biotech). The NK cell gating strategy for all 19 surface
markers that have been analyzed by flow cytometry is depicted
in Supplemental Figures 1, 2 performed on a representative
healthy donor sample. Dead NK cells have been excluded by
7AAD staining, and gates defining the positive percentage of NK
cell populations were set using positive, negative and internal
controls (Supplemental Figure 5).
ForMM cell phenotyping cells were stained with the following
antibodies: CD184 PE-Cy7, CD56 BV421 (BD Biosciences),
CD112 PE, CD261 PE, CD262 APC, CD95 BV412, HLA-
ABC BV605, HLA-E PE-Cy7, HLA-G APC (Biolegend), CD138
BV510, CD48 APC-H7 (Miltenyi), and CD155 FITC (R&D).
Dead cells have been excluded by DAPI-expression. The gating
strategy for all 11 surfacemarkers that have been analyzed by flow
cytometry is depicted in Supplemental Figure 4. Gates defining
the positive percentage of MM cells expressing a specific surface
marker were set using positive, negative and internal controls
(Supplemental Figure 6).
The purity of the isolated, autologous MM cells was
determined with the following antibodies: CD184 PE-Cy7, (BD
Biosciences), CD45 FITC (#6603838), CD56 APC (#IM2474)
(both from Beckmann Coulter), CD19 PerCP (Biolegend),
CD38 PE (DakoCytomation), and CD138 BV510 (Miltenyi
Biotech). MM cells were defined as DAPI-, CD45-/low, CD19-
, CD138+ and CD38+ as shown in Supplemental Figure 3.
Of note, CD138 staining following MM cell isolation was
often low due to the rapid internalization and the possible
competition with the CD138-beads used for the positive selection
procedure.
Analysis of Tumor Cell Death
MM tumor cells were stained with the Cell TraceTM Cell
Proliferation Kit (Invitrogen, #C34554), resuspended in X-VIVO
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10 media supplemented with 5% heat-inactivated human plasma
and 1% penicillin with streptomycin and seeded in a 96 V-bottom
well plate. NK cells were seeded into the corresponding wells. In
experiments where activated NK cells were used, the medium
was additionally supplemented with IL-2 (100 U/ml) and IL-
15 (10 ng/ml). All experiments were performed with an E:T
ratio of 2:1. The 96-well plates were incubated for 24 h at
37◦C with 5% CO2 atmospheric conditions. After incubation,
the cells were resuspended and transferred to FACS tubes.
Directly before measurement, 250 µl DAPI solution (DAPI
1:6000 in PBS) (AppliChem, #A4099,0010) was added to the
tubes and incubated for 3min. For each combination, two
wells were filled, representing technical replicates. In addition,
control wells for all tumor targets used in the experiment were
added, containing target cells only in order to determine the
spontaneous lysis. In the final evaluation of the experiment, the
specific lysis was calculated as the percentage of dead tumor
cells in the wells containing target and effector cells minus the
spontaneous lysis of the respective tumor cell condition. Through
this calculation of the specific lysis as the percentage of killed
tumor cells was attributed completely to the NK cell effector
function. Dead target cells were calculated as Cell Trace+DAPI+
cells.
Blocking Experiments
For blocking experiments NK cells were incubated for at
least 30min with 30µg/ml blocking antibody prior to co-
culture. Blocking experiments were performed with an anti-
NKG2A antibody (Beckman Coulter, #IM2750). As control
a Purified Mouse IgG2b isotype (Biolegend, #400302) was
used.
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